Broome Oncology LLC | Johnson City, PA

Research site

(Unclaimed)

Location

30 Harrison Street, Suite 100, Johnson City, Pennsylvania, United States of America

Site insights

Top conditions

Top treatments

Nivolumab

Pembrolizumab

LY2835219

Lenvatinib

Abemaciclib

Docetaxel

Sacituzumab

Rucaparib

Everolimus

MK-7902

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 16 total trials

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance tr...

Active, not recruiting

FIGO Stage III-IV

Newly Diagnosed

Drug: Placebo Oral Tablet

Drug: Rucaparib

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and t...

Active, not recruiting

Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Drug: Nab-Paclitaxel

Drug: Cisplatin

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early s...

Active, not recruiting

Breast Cancer

Drug: Standard Adjuvant Endocrine Therapy

Drug: Abemaciclib

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. (MAGNIFY)

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL. Lenalidomide is a...

Active, not recruiting

Lymphoma, Non-Hodgkin

Drug: Rituximab

Drug: Lenalidomide

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (CLEAR)

The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compar...

Active, not recruiting

Renal Cell Carcinoma

Drug: Sunitinib

Drug: Lenvatinib

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE)

This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanc...

Active, not recruiting

Metastatic Non-Squamous Non-Small Cell Lung Cancer

Drug: Sitravatinib

Drug: Docetaxel

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvat...

Active, not recruiting

Nonsquamous Non-small Cell Lung Cancer

Drug: Cisplatin

Drug: Placebo matching lenvatinib

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadju...

Active, not recruiting

Triple Negative Breast Neoplasms

Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim

Drug: Cyclophosphamide

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (EVOKE-01)

The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or meta...

Active, not recruiting

Non-Small Cell Lung Cancer

Biological: Sacituzumab Govitecan-hziy (SG)

Drug: Docetaxel